Rivervest Venture Management is an investment fund managing more than $6.82 billion ran by Sivan Weitzman. There are currently 4 companies in Mrs. Weitzman’s portfolio. The largest investments include Reneo Pharmaceuticals, Inc. and Spruce Bioscience, Inc., together worth $5.35 billion.
As of 17th July 2024, Rivervest Venture Management’s top holding is 2,534,220 shares of Reneo Pharmaceuticals, Inc. currently worth over $3.83 billion and making up 56.1% of the portfolio value.
In addition, the fund holds 2,936,281 shares of Spruce Bioscience, Inc. worth $1.52 billion.
The third-largest holding is Xilio Therapeutics, Inc. worth $1.37 billion and the next is Vapotherm Inc worth $112 million, with 52,881 shares owned.
Currently, Rivervest Venture Management's portfolio is worth at least $6.82 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Rivervest Venture Management office and employees reside in St. Louis, Missouri. According to the last 13-F report filed with the SEC, Sivan Weitzman serves as the Chief Financial Officer at Rivervest Venture Management.
The two most similar investment funds to Rivervest Venture Management are Invesco Asset Management and Qcm Cayman. They manage $6.83 billion and $6.85 billion respectively.
Rivervest Venture Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 1.6% of
the total portfolio value.
The fund focuses on investments in the United States as
25.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
25% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $43.8 million.
These positions were updated on July 24th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Reneo Pharmaceuticals, Inc. |
No change
2,534,220
|
$3,826,672,000 | 56.07% |
| Spruce Bioscience, Inc. |
No change
2,936,281
|
$1,520,114,000 | 22.27% |
| Xilio Therapeutics, Inc. |
No change
1,441,444
|
$1,365,768,000 | 20.01% |
| Vapotherm Inc |
No change
52,881
|
$112,282,000 | 1.65% |
| No transactions found | |||
| Showing first 500 out of 4 holdings | |||